123 related articles for article (PubMed ID: 37732735)
1. Targeted Therapy Win in BRAF-Mutant Gliomas.
Cancer Discov; 2023 Nov; 13(11):2299-2300. PubMed ID: 37732735
[TBL] [Abstract][Full Text] [Related]
2. Dabrafenib Effective in Pediatric Glioma.
Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673
[TBL] [Abstract][Full Text] [Related]
3. Dabrafenib plus trametinib in patients with BRAF
Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V
Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156
[TBL] [Abstract][Full Text] [Related]
4. Dabrafenib and trametinib in BRAFV600E mutated glioma.
Brown NF; Carter T; Kitchen N; Mulholland P
CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141
[TBL] [Abstract][Full Text] [Related]
5. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
6. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
[TBL] [Abstract][Full Text] [Related]
7. [Dabrafénib and tramétinib in BRAF V600E mutated pediatric gliomas].
Giorgis O; Doz F
Bull Cancer; 2024 May; 111(5):429-430. PubMed ID: 38471994
[No Abstract] [Full Text] [Related]
8. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
[TBL] [Abstract][Full Text] [Related]
9. Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With
Johanns TM; Ferguson CJ; Grierson PM; Dahiya S; Ansstas G
J Natl Compr Canc Netw; 2018 Jan; 16(1):4-10. PubMed ID: 29295876
[No Abstract] [Full Text] [Related]
10. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
11. Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.
Piña Y; Fusco MJ; Macaulay RJ; Walko CM; Peguero E; Evernden BR; Smalley KS; Forsyth P
J Neurol; 2020 Mar; 267(3):783-790. PubMed ID: 31748891
[TBL] [Abstract][Full Text] [Related]
12. Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.
Sasaki K; Nakamura Y; Baba N; Teramoto Y; Yamamoto A
Eur J Cancer; 2020 Nov; 139():37-40. PubMed ID: 32957012
[No Abstract] [Full Text] [Related]
13. Response of BRAF
Yamamoto G; Sakakibara-Konishi J; Ikari T; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
J Thorac Oncol; 2019 May; 14(5):e97-e99. PubMed ID: 31027751
[No Abstract] [Full Text] [Related]
14. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
15. Challenges of targeting
Smith-Cohn M; Davidson C; Colman H; Cohen AL
CNS Oncol; 2019 Dec; 8(4):CNS48. PubMed ID: 31818130
[No Abstract] [Full Text] [Related]
16. Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma.
Raswoli M; Nobre L; Hawkins C; Bartels UK; Tabori U; Bouffet E
Pediatr Blood Cancer; 2021 Jan; 68(1):e28561. PubMed ID: 32681754
[No Abstract] [Full Text] [Related]
17. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
18. Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models.
Li F; Bondra KM; Ghilu S; Studebaker A; Liu Q; Michalek JE; Kogiso M; Li XN; Kalapurakal JA; James CD; Burma S; Kurmasheva RT; Houghton PJ
Clin Cancer Res; 2022 Sep; 28(17):3836-3849. PubMed ID: 35797217
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
[TBL] [Abstract][Full Text] [Related]
20. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
[No Abstract] [Full Text] [Related]
[Next] [New Search]